Latest Insider Transactions at Natera, Inc. (NTRA)
This section provides a real-time view of insider transactions for Natera, Inc. (NTRA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Natera, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Natera, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
914
-1.25%
|
$82,260
$90.42 P/Share
|
|
Mar 28
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
2,662
-1.12%
|
$239,580
$90.42 P/Share
|
|
Mar 28
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
464
-0.41%
|
$41,760
$90.42 P/Share
|
|
Mar 28
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
707
-0.36%
|
$63,630
$90.42 P/Share
|
|
Mar 28
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
743
-0.36%
|
$66,870
$90.42 P/Share
|
|
Mar 28
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
1,000
-0.71%
|
$90,000
$90.13 P/Share
|
|
Mar 28
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
447
-0.06%
|
$40,230
$90.27 P/Share
|
|
Mar 27
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,292
+3.05%
|
-
|
|
Mar 27
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
5,184
+2.14%
|
-
|
|
Mar 27
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,364
+0.66%
|
-
|
|
Mar 27
2024
|
Jonathan Sheena |
BUY
Exercise of conversion of derivative security
|
Direct |
447
+0.13%
|
-
|
|
Mar 15
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Indirect |
50,910
-56.93%
|
$4,480,080
$88.85 P/Share
|
|
Mar 15
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
83,223
-9.68%
|
$7,323,624
$88.86 P/Share
|
|
Mar 15
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
68,270
+7.22%
|
$1,297,130
$19.58 P/Share
|
|
Mar 15
2024
|
Roelof Botha |
BUY
Exercise of conversion of derivative security
|
Direct |
19,924
+15.53%
|
$896,580
$45.64 P/Share
|
|
Mar 07
2024
|
Jonathan Sheena |
BUY
Bona fide gift
|
Indirect |
110,854
+44.16%
|
-
|
|
Mar 07
2024
|
Jonathan Sheena |
SELL
Bona fide gift
|
Direct |
110,854
-24.17%
|
-
|
|
Mar 06
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
5,000
-0.54%
|
$440,000
$88.79 P/Share
|
|
Mar 05
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
190,000
-4.79%
|
$16,720,000
$88.1 P/Share
|
|
Mar 05
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Direct |
1,012
-0.05%
|
$88,044
$87.81 P/Share
|
|
Mar 05
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
1,838
-0.8%
|
$159,906
$87.86 P/Share
|
|
Mar 05
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
2,245
-0.56%
|
$195,315
$87.85 P/Share
|
|
Mar 05
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,826
-3.85%
|
$248,688
$88.36 P/Share
|
|
Mar 05
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
9,326
-3.64%
|
$820,688
$88.36 P/Share
|
|
Mar 05
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,160
-1.05%
|
$190,080
$88.36 P/Share
|
|
Mar 05
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
1,028
-0.22%
|
$90,464
$88.36 P/Share
|
|
Mar 01
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,400
+2.12%
|
-
|
|
Mar 01
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
BUY
Grant, award, or other acquisition
|
Direct |
2,329
+1.17%
|
-
|
|
Mar 01
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,826
+3.7%
|
-
|
|
Mar 01
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
9,326
+3.51%
|
-
|
|
Mar 01
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,160
+1.04%
|
-
|
|
Mar 01
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
BUY
Grant, award, or other acquisition
|
Direct |
4,104
+0.38%
|
-
|
|
Mar 01
2024
|
Jonathan Sheena |
BUY
Grant, award, or other acquisition
|
Direct |
1,028
+0.22%
|
-
|
|
Feb 29
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,607
+3.05%
|
-
|
|
Feb 29
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
BUY
Grant, award, or other acquisition
|
Direct |
3,206
+1.57%
|
-
|
|
Feb 29
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
10,000
-0.53%
|
$870,000
$87.24 P/Share
|
|
Feb 29
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
6,000
-16.99%
|
$540,000
$90.01 P/Share
|
|
Feb 29
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
20,526
-2.33%
|
$1,785,762
$87.34 P/Share
|
|
Feb 29
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
20,526
+8.37%
|
$184,734
$9.29 P/Share
|
|
Feb 27
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
35,307
-14.74%
|
$2,648,025
$75.09 P/Share
|
|
Feb 27
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
35,307
+6.88%
|
$317,763
$9.85 P/Share
|
|
Feb 23
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
BUY
Exercise of conversion of derivative security
|
Indirect |
380,036
+26.57%
|
$760,072
$2.66 P/Share
|
|
Feb 16
2024
|
Herm Rosenman |
SELL
Open market or private sale
|
Direct |
93,901
-37.03%
|
$6,479,169
$69.47 P/Share
|
|
Feb 16
2024
|
Herm Rosenman |
BUY
Exercise of conversion of derivative security
|
Direct |
93,901
+37.64%
|
$187,802
$2.66 P/Share
|
|
Feb 07
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
5,000
-1.04%
|
$350,000
$70.1 P/Share
|
|
Feb 07
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
1,000
-2.75%
|
$70,000
$70.1 P/Share
|
|
Feb 06
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
34,029
-32.51%
|
$2,382,030
$70.03 P/Share
|
|
Feb 06
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
34,029
+14.86%
|
$476,406
$14.49 P/Share
|
|
Feb 06
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
6,000
-14.18%
|
$420,000
$70.0 P/Share
|
|
Feb 01
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
22,281
-23.98%
|
$1,492,827
$67.73 P/Share
|